Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Chest

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/chest.15-0627PMID 26110239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhaled corticosteroids in COPD: the clinical evidence

  2014cited by this paper
• Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study

  2014cited by this paper
• INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD

  2014cited by this paper
• Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

  2014cited by this paper
• Inhaled corticosteroids in COPD and the risk of serious pneumonia

  2013cited by this paper
• Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

  2013cited by this paper
• How far is real life from COPD therapy guidelines? An Italian observational study.

  2012cited by this paper
• Misdiagnosis of patients receiving inhaled therapies in primary care

  2010cited by this paper
• Inhaled corticosteroids and the risks of diabetes onset and progression.

  2010cited by this paper
• Identifying Individuals with Physcian Diagnosed COPD in Health Administrative Databases

  2009cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia.

  2007cited by this paper
• Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

  2007cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Low-dose inhaled and nasal corticosteroid use and the risk of cataracts

  2006cited by this paper
• Inhaled and nasal corticosteroid use and the risk of fracture.

  2004cited by this paper
• Validation of diagnostic codes within medical services claims.

  2004cited by this paper
• Association of inhaled corticosteroid use with cataract extraction in elderly patients.

  1998cited by this paper
• Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma.

  1997cited by this paper
• open access to scientific and medical research

  year unknowncited by this paper

• Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan

  2025cites this paper
• Effect of Preoperative Single-Inhaler Triple Therapy on Pulmonary Function in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease and FEV1 < 1.5 L

  2025cites this paper
• Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History

  2024cites this paper
• Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease – nationwide development from 1998 to 2018

  2024cites this paper
• Preoperative umeclidinium/vilanterol or tiotropium improves postoperative FEV1 in lung cancer patients with comorbid untreated chronic obstructive pulmonary disease

  2023cites this paper
• Methods to assess COPD medications adherence in healthcare databases: a systematic review

  2023cites this paper
• The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease

  2023cites this paper
• Glucocorticoid use in rheumatoid arthritis patients and the onset of pneumonia: a systematic review and meta-analysis

  2023cites this paper
• Research Progress on Discontinuation of ICS with Triple Inhaled Drugs for Chronic Obstructive Pulmonary Disease

  2022cites this paper
• De-Prescribing Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A Narrative Review

  2022cites this paper
• Prescribing of inhaled corticosteroids-containing and non-inhaled corticosteroids therapy in patients with chronic obstructive pulmonary disease at a Malaysian tertiary care center

  2022cites this paper
• Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey

  2022cites this paper
• Response to the Letter to the Editor Regarding “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Response to Letter]

  2021cites this paper
• COPD_A_315195 1227..1229

  2021cites this paper
• Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease

  2021cites this paper
• Inhaled corticosteroids increase risk of nontuberculous mycobacterial lung disease: a nested case control study and meta-analysis.

  2021cites this paper
• Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD

  2021cites this paper
• Towards Rational Prescription of Common Inhaler Medication in the Multimorbid COPD Patient

  2021cites this paper
• Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study

  2021cites this paper
• Smoking Cessation/Vaccinations.

  2020cites this paper
• Point of Care Portable Spirometry in the Diagnosis and Treatment of Inpatients with Chronic Obstructive Pulmonary Disease

  2020cites this paper
• Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane?

  2020cites this paper
• Association of Guideline-recommended COPD Inhaler Regimenswith Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial.

  2020cites this paper
• Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline

  2020cites this paper
• Initiating Low-Value Inhaled Corticosteroids in an Inception Cohort with COPD.

  2020cites this paper
• New guidelines for the management of Chronic Obstructive Pulmonary Disease (COPD) were released by the Global Initiative for Chronic Obstructive Lung Disease

  2020cites this paper
• Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings

  2020cites this paper
• Fluticasone Particles Bind to Motile Respiratory Cilia: A Mechanism for Enhanced Lung and Systemic Exposure?

  2020cites this paper
• Benefits and Risks of Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease Classified by Blood Eosinophil Counts

  2020cites this paper
• Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies

  2020cites this paper
• Chronic obstructive pulmonary disease research by using big data

  2020cites this paper
• COPD_A_269637 2889..2900

  2020cites this paper
• Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/ COPD Service for Primary Care

  2020cites this paper
• Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/ COPD Service for Primary Care

  2020cites this paper
• Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/ COPD Service for Primary Care

  2020cites this paper
• Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/COPD Service for Primary Care

  2019cites this paper
• Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms

  2019cites this paper
• De-implementing Inhaled Corticosteroids to Improve Care and Safety in COPD Treatment: Primary Care Providers’ Perspectives

  2019cites this paper
• Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study

  2019cites this paper
• The lung microbiome in obstructive airways disease: potential pathogenetic roles

  2019cites this paper
• Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status

  2019cites this paper
• Overuse and Misuse of Inhaled Corticosteroids Among Veterans with COPD: a Cross-sectional Study Evaluating Targets for De-implementation

  2019cites this paper
• COPD_A_207775 1267..1280

  2019influential citation
• Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate

  2019cites this paper
• Comparative Safety and Effectiveness of Inhaled Corticosteroids and Long-Acting β2 Agonist Combinations in Patients with Chronic Obstructive Pulmonary Disease.

  2019cites this paper
• University of Southern Denmark Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status Reilev,

  2019cites this paper
• Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD.

  2019cites this paper
• Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice

  2018cites this paper
• Безопасная отмена ингаляционной глюкокортикостероидной терапии у пациентов с хронической обструктивной болезнью легких

  2018cites this paper
• New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?

  2018cites this paper
• Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice

  2018cites this paper
• A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD

  2018cites this paper
• Effects of fluticasone propionate and budesonide on the expression of immune defense genes in bronchial epithelial cells.

  2018cites this paper
• Chronic Obstructive Pulmonary Diseases : Journal of the COPD Foundation New Treatment Options for COPD : How Do We Decide Phenotypes , Endotypes or Treatable Traits ?

  2018cites this paper
• Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same?

  2018cites this paper
• Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease

  2018cites this paper
• A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease

  2017cites this paper
• Chronic obstructive pulmonary disease in the long-term care setting: current practices, challenges, and unmet needs

  2017cites this paper
• Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

  2017cites this paper
• New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler.

  2017cites this paper
• Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies

  2017cites this paper
• Journal Club: Inhaled Corticosteroids- Refining Our Understanding of Their Role in Maintenance Treatment for COPD.

  2017cites this paper
• Inhaled Glucocorticoids and Pneumonia in Preterm Infants: Post Hoc Results from the NEuroSIS Trial

  2017cites this paper
• Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice

  2017cites this paper
• Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial

  2017cites this paper
• Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans.

  2017cites this paper
• Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study

  2017cites this paper
• Quoi de neuf en gériatrie

  2017cites this paper
• Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

  2017cites this paper
• Nuggets of Knowledge: COPD - targeting the use of inhaled corticosteroids.

  2016cites this paper
• The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study

  2016cites this paper
• Spread the Word About CHEST in 2016: An Ever-Rising Impact Factor, Content Innovations, Launching a New Partnership With Elsevier, and Protecting the Name and Legacy of the Journal.

  2016cites this paper
• Treatment options for moderate-to-very severe chronic obstructive pulmonary disease

  2016influential citation
• The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD

  2016cites this paper
• Precision respiratory medicine and the microbiome.

  2016cites this paper
• Budesonide and fluticasone propionate differentially affect the airway epithelial barrier

  2016cites this paper
• Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal

  2016cites this paper
• Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia

  2016cites this paper
• The Reemergence of the Asthma-COPD Overlap Syndrome: Characterizing a Syndrome in the Precision Medicine Era

  2016cites this paper
• Different characteristics associated with intensive care unit transfer from the medical ward between patients with acute exacerbations of chronic obstructive pulmonary disease with and without pneumonia.

  2016cites this paper
• Use of inhaled corticosteroids in COPD: improving efficacy

  2016cites this paper
• Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD

  2016cites this paper
• Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review

  2016cites this paper
• Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club: Do Inhaled Corticosteroids Reduce All-Cause Mortality in Chronic Obstructive Pulmonary Disease? What is the Latest Evidence?

  2016cites this paper
• Radiology corner

  2016cites this paper
• Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice

  2015cites this paper
• Inhaled Corticosteroids Are Associated with Pneumonia in COPD Patients

  2015cites this paper